Welcome to our dedicated page for Calidi Biotherapeutics SEC filings (Ticker: CLDI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Calidi Biotherapeutics, Inc. (CLDI) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Calidi is a clinical-stage immuno-oncology company listed on the NYSE American, and its filings offer detailed information on financial results, capital raises, material agreements, and progress in developing its RedTail oncolytic virus platform and lead candidate CLD-401.
Through current reports on Form 8-K, Calidi reports material events such as underwritten public offerings, changes in executive roles, establishment of a Scientific Advisory Board, and key development milestones, including preclinical data presentations for CLD-401 and updates on IND-enabling activities. These filings also reference press releases that describe how the RedTail platform is designed for systemic delivery, immune evasion, targeting of metastatic sites, and expression of genetic medicines like IL-15 superagonist in the tumor microenvironment.
Registration statements such as Form S-1 and periodic reports on Forms 10-K and 10-Q (when available) provide additional context on Calidi’s risk factors, financial condition, capital structure, and use of proceeds from securities offerings. Together, these documents help investors understand how the company funds its research and development in biotechnology and immuno-oncology.
On Stock Titan, CLDI filings are supplemented with AI-powered summaries that highlight key terms, financial metrics, and development updates from lengthy documents. Users can quickly scan new 8-Ks, 10-Qs, 10-Ks, and related exhibits, while also reviewing details on equity offerings, warrant terms, and other securities disclosures referenced in Calidi’s filings.
Calidi Biotherapeutics, Inc. reported continued operating losses, recording a net loss of $5.76 million for the quarter and $10.82 million for the six months ended June 30, 2025. The losses were driven by research and development and general and administrative expenses of $5.66 million for the quarter and $10.73 million for the six months. Loss per share was $1.99 for the quarter and $4.17 for the six months on weighted average shares of 2,877 and 2,569, respectively.
The company held $5.38 million of cash and restricted cash at period end after using $12.01 million of cash in operating activities during the six months. Total assets declined to $9.35 million and total liabilities declined to $7.28 million, leaving total equity of $2.08 million and an accumulated deficit of $132.4 million. Management discloses substantial doubt about the company’s ability to continue as a going concern within 12 months and intends to seek additional financing. During the period the company raised approximately $10.08 million from public and registered direct offerings and exercises, and recorded warrant liabilities totaling about $0.10 million. The company effected reverse stock splits (a prior 1-for-10 and a 1-for-12 reverse split) and retrospectively restated shares and per-share amounts for all periods presented.
Calidi Biotherapeutics furnished a press release announcing its financial results for the quarter ended June 30, 2025 and certain recent corporate developments. The release is incorporated by reference in this Current Report and is furnished as Exhibit 99.1 under Item 2.02, with the same information referenced under Item 7.01 as a Regulation FD disclosure.
The company states that the information is being furnished, not filed, and therefore is not subject to Section 18 liability nor automatically incorporated by reference into other securities filings. The report is signed on behalf of the company by Andrew Jackson, Chief Financial Officer. The press release text and any financial detail must be consulted in Exhibit 99.1, as this report does not include the actual financial figures.